[
  {
    "ts": null,
    "headline": "What Do Analysts Think About Vertex Pharmaceuticals (VRTX)?",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform rating by Scotiabank on November 12 with a $495 price target. The same day, Evercore ISI reiterated a Buy rating on the stock. However, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]",
    "url": "https://finnhub.io/api/news?id=c48d3014983de4d337c2c154393aae061a8b723bc85c1993171c30cc1b456236",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764186597,
      "headline": "What Do Analysts Think About Vertex Pharmaceuticals (VRTX)?",
      "id": 137619192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform rating by Scotiabank on November 12 with a $495 price target. The same day, Evercore ISI reiterated a Buy rating on the stock. However, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]",
      "url": "https://finnhub.io/api/news?id=c48d3014983de4d337c2c154393aae061a8b723bc85c1993171c30cc1b456236"
    }
  }
]